论文部分内容阅读
近10多年的临床试验已证明:阿斯匹林是一种有效的抗血栓药物,其抗血栓作用归于抑制血小板的功能。阿斯匹林抗血栓最合适剂量尚有争论。小剂量阿斯匹林(300毫克或更小)有选择性抑制血栓素A_2(TXA_2)的作用,由于阿斯匹林的副作用是由剂量决定的,许多临床情况需长期使用,甚至无限期地使用,故适于使用小剂量。为了寻找一个既能阻止TXA_2的产生又不抑制前列腺环素(PGI_2)产生的阿斯匹林的剂量,曾进行过许多实验。Burch等提出:血小板中环氧化酶比
Nearly 10 years of clinical trials have proved: aspirin is a potent antithrombotic drug, its anti-thrombotic effect attributed to the inhibition of platelet function. The most appropriate dose of aspirin antithrombotic controversy. Low-dose aspirin (300 mg or less) selectively inhibits thromboxane A 2 (TXA 2). As aspirin side effects are dose-dependent, many clinical conditions require long-term use, even indefinitely Use, it is suitable for the use of small doses. In an attempt to find a dose of aspirin that blocks both the production of TXA 2 and the production of prostacyclin (PGI 2), many experiments have been conducted. Burch and other proposed: platelet cyclooxygenase ratio